Proactive - Interviews for investors podcast

Tonix Pharmaceuticals and Makana partner to advance research with Anti-Rejection therapy

0:00
4:52
Reculer de 15 secondes
Avancer de 15 secondes
Tonix Pharmaceuticals Holdings has announced a groundbreaking collaborative research agreement with Makana Therapeutics, aiming to explore the potential of TNX-1500, Tonix’s anti-CD40L monoclonal antibody candidate, in advancing the field of xenotransplantation—the transplantation of animal-derived organs into human patients. In an interview with Steve Darling from Proactive, Tonix CEO Dr. Seth Lederman shared details of the preclinical partnership, which will evaluate TNX-1500 in combination with Makana’s proprietary human-compatible organs and cells, derived from genetically engineered pigs. The collaboration will initially focus on kidney, heart, and islet cell transplant models, with the broader objective of developing new treatment options for patients suffering from organ failure. The preclinical studies are designed to generate data to support a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration, with the goal of enabling compassionate use of xenotransplantation therapies in patients who have no alternative treatment options. Makana’s approach centers around genetically engineered pigs that have been modified to lack swine leukocyte antigen (SLA), a key driver of immune rejection. These animals demonstrate enhanced compatibility with human biology and offer several potential advantages over competing technologies, including high fertility rates, increased litter sizes, and robust health profiles—key factors that support scalability and commercial viability in global markets. TNX-1500 is a next-generation anti-CD40L monoclonal antibody designed to modulate immune response while minimizing the risk of thrombosis—a common side effect associated with earlier anti-CD40L agents. The drug candidate holds promise in preventing organ transplant rejection, making it an ideal component of xenotransplantation protocols. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

D'autres épisodes de "Proactive - Interviews for investors"